Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036915 | 1.00 | CYP2D6 (0.46) | CYP2D6CYP1A2POLBSTAT3TSHR | |
| SCHEMBL6906071 | 1.00 | CYP2D6 (0.46) | CYP2D6CYP1A2POLBSTAT3TSHR | |
| SCHEMBL6906066 | 1.00 | CYP2D6 (0.46) | CYP2D6CYP1A2POLBSTAT3TSHR | |
| SCHEMBL22470428 | 0.90 | CYP2D6 (0.46) | CYP2D6CYP1A2POLBSTAT3TSHR | |
| SCHEMBL15366816 | 0.90 | CYP2D6 (0.46) | CYP2D6CYP1A2POLBSTAT3TSHR | |
| SCHEMBL26694981 | 0.86 | STAT3 (0.37) | CYP2D6CYP1A2POLBSTAT3TSHR | |
| SCHEMBL1541453 | 0.85 | CYP2D6 (0.42) | CYP2D6CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL1543877 | 0.85 | CYP2D6 (0.42) | CYP2D6CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29563225 | 0.85 | CYP2D6 (0.42) | CYP2D6CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL1541455 | 0.85 | CYP2D6 (0.42) | CYP2D6CYP1A2POLBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463728-B1 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| US-7432267-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMAPNY (US) | 2008-10-07 | — | — | US | disclosed |
| US-7001911-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20050282813-A1 | Fused cyclic modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-22 | — | — | US | disclosed |
| US-20050256048-A1 | Selective androgen receptor modulators and methods for their identification, design and use | SALVATI MARK E | 2005-11-17 | — | — | US | disclosed |
| US-6960474-B2 | Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-22 | — | — | US | disclosed |
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-19 | — | — | US | disclosed |
| EP-1299385-A2 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1299094-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR IDENTIFICATION, DESIGN AND USE | Bristol-Myers Squibb Company (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020173445-A1 | Selective androgen receptor modulators and methods for their identification, design and use | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-21 | — | — | US | disclosed |
| WO-2002000617-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR IDENTIFICATION, DESIGN AND USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2002000653-A2 | FUSED CYCLIC COMPOUNDS AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256048-A1 | Selective androgen receptor modulators and methods for their identification, design and use | AR, FSHR, LHCGR | CYP2D6 1522/4885CYP1A2 969/4885POLB 4192/4885 |
| US-20050282813-A1 | Fused cyclic modulators of nuclear hormone receptor function | NR2C2, NR0B2, NR0B1 | CYP2D6 432/4885CYP1A2 1350/4885POLB 4094/4885 |
| US-20020173445-A1 | Selective androgen receptor modulators and methods for their identification, design and use | AR, FSHR, LHCGR | CYP2D6 1522/4885CYP1A2 969/4885POLB 4192/4885 |
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | CYP2D6 3855/4885CYP1A2 3318/4885POLB 2511/4885 |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | CYP2D6 3855/4885CYP1A2 3318/4885POLB 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.